{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:31Z","timestamp":1788922171824,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA050629"],"award-info":[{"award-number":["R01DA050629"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["1819-HQ-000036"],"award-info":[{"award-number":["1819-HQ-000036"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jsat.2021.108647","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T18:46:44Z","timestamp":1635274004000},"page":"108647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada"],"prefix":"10.1016","volume":"133","author":[{"given":"Megan","family":"Kurz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jsat.2021.108647_bb0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"National practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2021.108647_bb0010","series-title":"Provincial guideline for the clinical management of high-risk drinking and alcohol use disorder","year":"2019"},{"key":"10.1016\/j.jsat.2021.108647_bb0015","author":"BC Mental Health and Substance Use Services"},{"key":"10.1016\/j.jsat.2021.108647_bb0020","author":"BC Mental Health and Substance Use Services"},{"key":"10.1016\/j.jsat.2021.108647_bb0040","series-title":"PharmaNet","year":"2018"},{"key":"10.1016\/j.jsat.2021.108647_bb0025","series-title":"Discharge abstract database (hospital separations)","year":"2018"},{"key":"10.1016\/j.jsat.2021.108647_bb0030","series-title":"Medical services plan (MSP) payment information file","year":"2018"},{"key":"10.1016\/j.jsat.2021.108647_bb0035","series-title":"National ambulatory care reporting system (NACRS)","year":"2018"},{"key":"10.1016\/j.jsat.2021.108647_bb0045","series-title":"Vital statistics deaths","year":"2018"},{"key":"10.1016\/j.jsat.2021.108647_bb0050","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jsat.2021.108647_bb0055","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","article-title":"Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009","volume":"159","author":"Binswanger","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2021.108647_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2014a high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2021.108647_bb0070","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: A national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.jsat.2021.108647_bb0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia","volume":"110","author":"Burns","year":"2014","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.jsat.2021.108647_bb0080","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108647_bb0085","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in new SouthWales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108647_bb0090","series-title":"CRISM national guidelines for the clinical management of opioid use disorder","year":"2018"},{"key":"10.1016\/j.jsat.2021.108647_bb0095","series-title":"Buprenorphine\/naloxone for opioid dependence: Clinical practice guideline.","year":"2011"},{"issue":"8","key":"10.1016\/j.jsat.2021.108647_bb0100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00005650-199508000-00004","article-title":"A chronic disease score with empirically derived weights","volume":"33","author":"Clark","year":"1995","journal-title":"Medical Care"},{"key":"10.1016\/j.jsat.2021.108647_bb0105","series-title":"Methadone maintenance program: Clinical practice guideline","year":"2014"},{"key":"10.1016\/j.jsat.2021.108647_bb0115","series-title":"Practice standard: Prescribing methadone","year":"2018"},{"key":"10.1016\/j.jsat.2021.108647_bb0120","series-title":"National guidelines for medication assisted treatment of opioid dependence","year":"2014"},{"issue":"2","key":"10.1016\/j.jsat.2021.108647_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108647_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK general practice research database","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jsat.2021.108647_bb0135","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/070674370505001013","article-title":"Comorbidity of major depression with substance use disorders","volume":"50","author":"Currie","year":"2005","journal-title":"The Canadian Journal of Psychiatry"},{"issue":"8","key":"10.1016\/j.jsat.2021.108647_bb0140","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/add.12536","article-title":"The impact of opioid substitution therapy on mortality post-release from prison: Retrospective data linkage study","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2021.108647_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108647_bb0150","first-page":"149","article-title":"The Max Clinic: Medical care designed to engage the hardest-to-reach persons living with HIV in Seattle and King County,Washington","volume":"32","author":"Dombrowski","year":"2018"},{"issue":"3","key":"10.1016\/j.jsat.2021.108647_bb0155","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.addbeh.2013.11.022","article-title":"Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: Systematic review and meta-analyses","volume":"39","author":"Goldner","year":"2014","journal-title":"Addictive Behaviors"},{"issue":"16","key":"10.1016\/j.jsat.2021.108647_bb0160","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/jama.2017.13358","volume":"318","author":"Gostin","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jsat.2021.108647_bb0185","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"4","key":"10.1016\/j.jsat.2021.108647_bb0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2021.108647_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003057","article-title":"Addressing disparities in the health of persons with HIV attributable to unstable housing in the United States: The role of the Ryan white HIV\/AIDS program","volume":"17","author":"Griffin","year":"2020","journal-title":"PLoS Medicine"},{"issue":"7","key":"10.1016\/j.jsat.2021.108647_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157512","article-title":"Drug toxicity deaths after release from incarceration in Ontario, 2006\u20132013: Review of Coroner's cases","volume":"11","author":"Groot","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jsat.2021.108647_bb0205","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: Patients' reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2021.108647_bb0210","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jsat.2008.07.002","article-title":"Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program","volume":"36","author":"Havens","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108647_bb0225","series-title":"Clinical guidelines for opioid substitution treatment","year":"2017"},{"key":"10.1016\/j.jsat.2021.108647_bb0230","first-page":"758","volume":"183","author":"Hernan","year":"2016"},{"issue":"3","key":"10.1016\/j.jsat.2021.108647_bb0235","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/2150131914560610","article-title":"Barriers to prescription medication adherence among homeless and vulnerably housed adults in three Canadian cities","volume":"6","author":"Hunter","year":"2015","journal-title":"Journal of Primary Care & Community Health"},{"issue":"7","key":"10.1016\/j.jsat.2021.108647_bb0240","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ajad.12288","article-title":"Treatment outcomes in opioid dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories","volume":"24","author":"Jacobs","year":"2015","journal-title":"The American Journal on Addictions"},{"issue":"18","key":"10.1016\/j.jsat.2021.108647_bb0245","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"The New England Journal of Medicine"},{"issue":"20","key":"10.1016\/j.jsat.2021.108647_bb0250","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jsat.2021.108647_bb0255","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.9778\/cmajo.20150098","article-title":"Mortality over 12 years of follow-up in people admitted to provincial custody in Ontario: A retrospective cohort study","volume":"4","author":"Kouyoumdjian","year":"2016","journal-title":"CMAJ Open"},{"issue":"4","key":"10.1016\/j.jsat.2021.108647_bb0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108647_bb0265","series-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014"},{"issue":"1","key":"10.1016\/j.jsat.2021.108647_bb0270","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/apc.2011.0169","article-title":"Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting","volume":"26","author":"Milloy","year":"2012","journal-title":"AIDS Patient Care and STDs"},{"key":"10.1016\/j.jsat.2021.108647_bb0275","series-title":"BC corrections dataset","year":"2018"},{"issue":"6","key":"10.1016\/j.jsat.2021.108647_bb0280","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/aje\/kwp186","article-title":"Proportional hazards frailty models for recurrent methadone maintenance treatment","volume":"170","author":"Nosyk","year":"2009","journal-title":"American Journal of Epidemiology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108647_bb0285","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2010.03.008","article-title":"Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996\u20132006","volume":"39","author":"Nosyk","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.jsat.2021.108647_bb0290","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/cid\/civ476","article-title":"The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among HIV-positive people who inject drugs","volume":"61","author":"Nosyk","year":"2015","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2021.108647_bb0295","series-title":"BC opioid substitution treatment system performance measures 2014\/15 - 2015\/16","year":"2017"},{"issue":"1","key":"10.1016\/j.jsat.2021.108647_bb0300","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","article-title":"Buprenorphine: A controlled clinical trial in the treatment of opioid dependence","volume":"60","author":"Pani","year":"2000","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108647_bb0305","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: Population based retrospective cohort study","volume":"338","author":"Pearce","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jsat.2021.108647_bb0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10550880802324382","article-title":"One-year and cumulative retention as predictors of success in methadone maintenance treatment: A comparison of two clinics in the United States and Israel","volume":"27","author":"Peles","year":"2008","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2021.108647_bb0315","series-title":"British Columbia perinatal data registry","year":"2018"},{"issue":"7","key":"10.1016\/j.jsat.2021.108647_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132664","article-title":"Identifying homelessness among veterans using VA administrative data: Opportunities to expand detection criteria","volume":"10","author":"Peterson","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jsat.2021.108647_bb0325","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jsat.2010.07.009","article-title":"The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment","volume":"39","author":"Pinto","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108647_bb0330","doi-asserted-by":"crossref","first-page":"e036102","DOI":"10.1136\/bmjopen-2019-036102","article-title":"Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada","volume":"10","author":"Piske","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jsat.2021.108647_bb0335","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1037\/a0037550","article-title":"A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: Findings from a retrospective multisite study","volume":"22","author":"Proctor","year":"2014","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108647_bb0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp053113","article-title":"Mood disorders and substance use disorder: A complex comorbidity","volume":"3","author":"Quello","year":"2005","journal-title":"Science & Practice Perspectives"},{"issue":"11","key":"10.1016\/j.jsat.2021.108647_bb0345","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1176\/ps.50.11.1427","article-title":"Co-occurring severe mental illness and substance use disorders: A review of recent research","volume":"50","author":"RachBeisel","year":"1999","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.jsat.2021.108647_bb0350","series-title":"Adult correctional statistics in Canada, 2015\/2016","author":"Reitano","year":"2017"},{"issue":"3","key":"10.1016\/j.jsat.2021.108647_bb0355","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-5618.2006.00314.x","article-title":"Treatment adherence with antipsychotic medications in bipolar disorder","volume":"8","author":"Sajatovic","year":"2006","journal-title":"Bipolar Disorders"},{"issue":"4","key":"10.1016\/j.jsat.2021.108647_bb0360","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2307\/2533673","article-title":"A general framework for random effects survival analysis in the cox proportional hazards setting","volume":"54","author":"Sargent","year":"1998","journal-title":"Biometrics"},{"issue":"9","key":"10.1016\/j.jsat.2021.108647_bb0365","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jama.2012.234","article-title":"Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan","volume":"307","author":"Seal","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2021.108647_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102696","article-title":"Trajectories of retention in opioid agonist therapy in a Canadian setting","volume":"77","author":"Soc\u00edas","year":"2020","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2021.108647_bb0375","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.jsat.2021.108647_bb0380","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1001\/archinte.166.19.2087","article-title":"Association between mental health disorders, problem drug use, and regular prescription opioid use","volume":"166","author":"Sullivan","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108647_bb0390","series-title":"Package 'survival'","author":"Therneau","year":"2021"},{"key":"10.1016\/j.jsat.2021.108647_bb0395","series-title":"A guideline for clinical management of opioid addiction","author":"Vancouver Coastal Health","year":"2015"},{"key":"10.1016\/j.jsat.2021.108647_bb0400","series-title":"Prisons and health","year":"2014"},{"key":"10.1016\/j.jsat.2021.108647_bb0405","article-title":"A systematic review of criminal recidivism rates worldwide: 3-Year update","volume":"4","author":"Yukhnenko","year":"2019"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:55:58Z","timestamp":1760039758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221003731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":72,"alternative-id":["S0740547221003731"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108647","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108647"}}